IL‐17, GAL‐10, and TGF‐β are promising noninvasive biomarkers of pediatric eosinophilic esophagitis

Documenti analoghi

• Unveiling a suspected dupilumab‐induced neuropathy in pediatric eosinophilic esophagitis
  di: Hugo Gagnon, et al.
  Pubblicazione: (2024)
• Azelastine‐fluticasone intranasal therapy: A paradigm shift in pediatric allergic rhinitis management. A point of view of the Italian Society of Pediatric Allergy and Immunology
  di: Gianluigi Marseglia, et al.
  Pubblicazione: (2026)
• Medical treatment of eosinophilic esophagitis
  di: Hannah F. Marshall, et al.
  Pubblicazione: (2024)
• Proton pump inhibitor effect on esophageal protein signature of eosinophilic esophagitis, prediction, and evaluation of treatment response
  di: Francisca Molina‐Jiménez, et al.
  Pubblicazione: (2024)
• Editorial comment on “The Naples pediatric food allergy score: A multivariable model for the prediction of food allergy in children”
  di: Martina Votto, et al.
  Pubblicazione: (2025)